R-spondins can potentiate WNT signaling without LGRs

Andres M Lebensohn¹,²*, Rajat Rohatgi¹,²*

¹Department of Biochemistry, Stanford University School of Medicine, Stanford, United States; ²Department of Medicine, Stanford University School of Medicine, Stanford, United States

Abstract The WNT signaling pathway regulates patterning and morphogenesis during development and promotes tissue renewal and regeneration in adults. The R-spondin (RSPO) family of four secreted proteins, RSPO1-4, amplifies target cell sensitivity to WNT ligands by increasing WNT receptor levels. Leucine-rich repeat-containing G-protein coupled receptors (LGRs) 4-6 are considered obligate high-affinity receptors for RSPOs. We discovered that RSPO2 and RSPO3, but not RSPO1 or RSPO4, can potentiate WNT/β-catenin signaling in the absence of all three LGRs. By mapping the domains on RSPO3 that are necessary and sufficient for this activity, we show that the requirement for LGRs is dictated by the interaction between RSPOs and the ZNRF3/RNF43 E3 ubiquitin ligases and that LGR-independent signaling depends on heparan sulfate proteoglycans (HSPGs). We propose that RSPOs can potentiate WNT signals through distinct mechanisms that differ in their use of either LGRs or HSPGs, with implications for understanding their biological functions.

DOI: https://doi.org/10.7554/eLife.33126.001

Introduction

The WNT signaling pathway regulates patterning and morphogenesis during development (Hoppler and Moon, 2014). In adults, WNT ligands promote the renewal of stem cells, maintaining tissue homeostasis during routine turnover or following injury (Clevers et al., 2014). Some WNT responses in vertebrates depend on a second signal provided by the R-spondin (RSPO) family of four secreted proteins (de Lau et al., 2012). RSPOs have emerged as important stroma-derived growth factors that drive the renewal of epithelial stem cells in many adult vertebrate tissues (de Lau et al., 2014). RSPOs markedly amplify target cell sensitivity to WNT ligands by neutralizing two transmembrane E3 ubiquitin ligases, ZNRF3 and RNF43, which reduce cell-surface levels of WNT receptors (Hao et al., 2012; Koo et al., 2012). Indeed, chromosomal translocations that increase RSPO expression or mutations that inactivate ZNRF3/RNF43 can drive cancer (Hao et al., 2016).

RSPOs contain tandem furin-like repeats (FU1 and FU2), a thrombospondin type 1 (TSP) domain and a basic region (BR). RSPOs simultaneously engage ZNRF3/RNF43 through their FU1 domain and leucine-rich repeat-containing G-protein coupled receptors (LGRs) 4-6 through their FU2 domain (Chen et al., 2013; Peng et al., 2013; Wang et al., 2013; Xu et al., 2013; Zebisch et al., 2013), triggering the clearance of ZNRF3/RNF43 and the consequent rise in WNT receptor levels on the cell surface. LGR4-6 are selectively expressed in various tissue stem cells (Clevers et al., 2014) and are considered the primary high-affinity receptors for RSPOs (Carmon et al., 2011; de Lau et al., 2011; Glinka et al., 2011).

We now show that RSPO2 and RSPO3, but not RSPO1 or RSPO4, can potentiate WNT/β-catenin signaling in the absence of all three LGRs. Using purified mutant and chimeric RSPOs and cell lines lacking various receptors, we elucidated the requirements for this mode of signaling. The ZNRF3/RNF43-interacting FU1 domain is necessary for LGR-independent signaling, while the LGR-
interacting FU2 domain is dispensable. The FU1 domain of RSPO3 is also sufficient to confer the capacity to signal without LGRs when transplanted to RSPO1. The TSP/BR domains of RSPOs and their interaction with heparan sulfate proteoglycans (HSPGs), previously considered dispensable for potentiation of WNT/β-catenin signaling (Kazanskaya et al., 2004; Ohkawara et al., 2011), are essential in the absence of LGRs. These results define two alternative modes of RSPO-mediated signaling that share a common dependence on ZNRF3/RNF43, but differ in their use of either LGRs or HSPGs.

Results

In previous work (Lebensohn et al., 2016), we generated and thoroughly characterized a haploid human cell line (HAP1-7TGP) that harbors a fluorescent transcriptional reporter for WNT/β-catenin signaling. Both the fluorescence of this synthetic reporter and the transcription of endogenous WNT target genes in HAP1-7TGP cells can be activated by WNT ligands and these WNT responses can be strongly potentiated by RSPOs (Lebensohn et al., 2016). HAP1-7TGP cells do not secrete WNT ligands and thus their response to RSPOs requires the co-administration of a low concentration of WNT. A comprehensive set of unbiased genetic screens in HAP1-7TGP cells identified many of the known components required for a signaling response to WNT and RSPO ligands, establishing this cell line as a valid and genetically tractable system to study this pathway (Lebensohn et al., 2016).

We made the serendipitous and unexpected observation that RSPO3 could potently enhance WNT reporter fluorescence driven by a low concentration of WNT3A in two independently derived HAP1-7TGP clonal cell lines carrying loss-of-function mutations in LGR4 (LGR4KO cells; see Materials and methods and Supplementary file 1) (Figure 1A). In contrast, RSPO1 did not enhance the response to WNT3A in LGR4KO cells. RSPO1 and RSPO3 had equivalent activity in wild-type (WT) HAP1-7TGP cells, demonstrating that both ligands were functional, and the response to RSPO3 in both WT and LGR4KO cells depended on the presence of WNT3A (Figure 1A).

While LGR4 is the only RSPO receptor expressed in HAP1 cells (Table 1) (Dubey et al., 2016), we excluded the possibility of compensatory up-regulation of LGR5 or LGR6 by simultaneously disrupting both genes in LGR4KO cells, generating multiple independent clonal cell lines lacking all three RSPO receptors (hereafter called LGR4/5/6KO cells; Supplementary file 1). LGR4/5/6KO cells retained an intact WNT signaling cascade, responding normally to a saturating dose of WNT3A (Figure 1B). All four RSPOs (1-4) strongly potentiated WNT signaling in WT cells, establishing ligand integrity. However, RSPO1 and RSPO4 were completely inactive in LGR4/5/6KO cells, even at concentrations that induced maximum WNT reporter induction in WT cells, whereas RSPO2 and RSPO3 strongly potentiated signaling driven by low concentrations of WNT3A in the absence of all three LGRs (Figure 1B). Therefore, RSPO2 and RSPO3 possess a unique quality absent in RSPO1 and RSPO4 that enables them to potentiate WNT responses without LGRs.

Dose-response analysis revealed that RSPO1 and RSPO3 enhanced WNT signaling in WT cells with nearly identical pharmacodynamics—both the efficacy (maximum reporter activity) and the potency (measured by the EC50, defined as the RSPO concentration that induced half-maximum reporter activity) were similar for both ligands (Figure 1C). In LGR4/5/6KO cells, RSPO1 had no detectable activity at concentrations up to 160 ng/ml, 400-fold higher than its EC50 in WT cells. While RSPO3 potentiated WNT signaling in LGR4/5/6KO cells, its efficacy was reduced by 33% and its EC50 was increased by 16-fold compared to WT cells (Figure 1C). The distinct pharmacodynamics of RSPO3 in the two cell types suggested that its reception was mediated by different mechanisms in the presence and absence of LGRs.

We sought to determine which domains of RSPO3 were required for LGR-independent signaling using a ligand mutagenesis strategy (Figure 2A). Our experimental strategy leveraged a comparison between RSPO1 and RSPO3, since the former depended strictly on LGRs while the latter could signal in their absence. Unless otherwise noted, each WT and mutant RSPO ligand described hereafter was produced as a fusion protein carrying an N-terminal hemagglutinin (HA) tag and a tandem C-terminal tag composed of an immunoglobulin fragment crystallizable (Fc) domain followed by a 1D4 epitope tag (Molday and Molday, 2014) used for immuno-affinity purification (see Materials and methods and Figure 1—figure supplement 1A and B for a description of ligand purification and characterization). Importantly, the pharmacodynamics of the tagged RSPO proteins were similar to
Figure 1. RSPO2 and RSPO3 can potentiate WNT signaling in the absence of LGR4, LGR5 and LGR6. (A) WNT reporter fluorescence (median ± standard error of the median (SEM) from 10,000 cells) for WT HAP1-7TGP and two distinct LGR4 KO clonal cell lines (determined by genotyping, Supplementary file 1) following treatment with the indicated combinations of WNT3A conditioned media (CM) and untagged, recombinant RSPO1 or RSPO3 (both at 20 ng/ml). All cell lines responded similarly to a saturating dose of WNT3A, demonstrating an intact downstream signaling response. (B) Figure 1 continued on next page
those of their untagged counterparts in both WT and LGR4/5/6KO cells (Figure 1—figure supplement 1C and D).

Previous studies have shown that the FU1 and FU2 domains in all RSPOs, which bind to ZNRF3/RNF43 and LGRs, respectively, are both necessary and sufficient to potentiate WNT responses, while the TSP and BR domains are dispensable (Kazanskaya et al., 2004). Simultaneous deletion of the FU1 and FU2 domains of RSPO3 abolished signaling in both WT and LGR4/5/6KO cells (Figure 2B). Point mutations in the FU1 domain of RSPO3 (R67A/Q72A; Figure 2A) known to weaken the interaction between RSPOs and ZNRF3/RNF43 (Xie et al., 2013) entirely abolished RSPO3 signaling in LGR4/5/6KO cells (Figure 2B and D) and substantially reduced (but did not abolish) RSPO3 signaling in WT cells (EC50 increased by 21-fold; Figure 2B and C). Thus, the reduction in the affinity between RSPO3 and ZNRF3/RNF43 caused by the FU1 R67A/Q72A mutation impaired LGR-independent signaling to a much greater extent than LGR-dependent signaling. Indeed, the equivalent R66A/Q71A mutation in RSPO1 (Figure 2A), which only signals in an LGR-dependent manner, also impaired but did not completely abolish signaling in WT cells (Figure 2B).

Point mutations in the FU2 domain of RSPO3 (F106E/F110E; Figure 2A) that weaken interactions with LGRs (Xie et al., 2013) had little impact on RSPO3 signaling in LGR4/5/6KO cells, consistent with the lack of LGRs in these cells (Figure 2B and D). In WT cells, the F106E/F110E mutation in RSPO3 did not prevent signaling, but reduced the efficacy by 48% and increased the EC50 by 2.9-fold (Figure 2C). Thus, RSPO3 signaling in WT cells includes contributions from both LGR-dependent and independent pathways. In contrast, the F106E/F110E mutation in RSPO1 abolished signaling in WT cells, demonstrating that signaling by RSPO1 depends entirely on its interaction with LGRs (Figure 2B).

The C-terminal TSP and BR domains of RSPOs (denoted TSP/BR when discussed together) are considered dispensable for LGR-mediated signaling (Glinka et al., 2011). When we deleted these domains individually in RSPO3, there were only minor effects on signaling in WT cells (Figure 2E and F). Deletion of both domains in RSPO3

Table 1. Relative gene expression level in HAP1 cells of selected genes discussed in this work. RPKM (Reads Per Kilobase of transcript per Million mapped reads) values from duplicate RNA-seq datasets described previously (NCBI GEO accession number GSE75515, https://www.ncbi.nlm.nih.gov/geo/), obtained from two different passages of WT HAP1 cells (Dubey et al., 2016).

| Gene     | Replicate 1 | Replicate 2 | Average |
|----------|-------------|-------------|---------|
| LGR4     | 160.61      | 174.69      | 167.65  |
| LGR5     | 0.02        | 0.00        | 0.01    |
| LGR6     | 0.02        | 0.00        | 0.01    |
| ZNRF3    | 30.9        | 33.3        | 32.1    |
| RNF43    | 0.12        | 0.08        | 0.1     |
| GPC1     | 49.55       | 47.53       | 48.54   |
| GPC2     | 4.17        | 4.79        | 4.48    |
| GPC3     | 170.22      | 144.37      | 157.29  |
| GPC4     | 209.39      | 229.86      | 219.63  |
| GPC5     | 0.1         | 0.1         | 0.1     |
| GPC6     | 13.88       | 14.90       | 14.39   |
| SDC1     | 51.37       | 47.88       | 49.63   |
| SDC2     | 11.42       | 9.2         | 10.31   |
| SDC3     | 43.58       | 50.64       | 47.11   |
| SDC4     | 8.16        | 8.21        | 8.18    |

DOI: https://doi.org/10.7554/eLife.33126.004
Figure 2. Domains of RSPO3 required for LGR-independent signaling. (A) Schematic representation of human WT and mutant RSPO1 (salmon) and RSPO3 (violet) proteins produced and purified as described in Materials and methods and Figure 1—figure supplement 1A. The N-terminal HA and C-terminal Fc and 1D4 tags present in all constructs are not shown. Amino acid numbers for human RSPO1 and RSPO3 (UniProt accession number Q2MKA7 and Q9BXY4, respectively) are indicated below and arrows show mutations made in the FU1 and FU2 domains. Polypeptide lengths are drawn
increased the EC50 in WT cells by 333-fold, but did not change the efficacy (Figure 2F). Therefore, while the TSP/BR domains are not essential for signaling in WT cells, consistent with prior work, their loss substantially reduces the potency of RSPO3. In contrast, RSPO3 lacking the TSP/BR domains failed to potentiate WNT responses in LGR4/5/6 KO cells at the concentrations tested (Figure 2E and G). The signaling properties of RSPO3 lacking the TSP/BR domains were unchanged when the dimerizing Fc tag was removed (Figure 2F and G).

These mutagenesis experiments demonstrated that the FU1 and TSP/BR domains of RSPO3 are required for its ability to potentiate WNT responses in the absence of LGRs, while the FU2 domain is dispensable. These domain requirements are distinct from those for LGR-mediated signaling by RSPO1, which depends on the FU1 and FU2, but not on the TSP/BR domains. In WT cells, RSPO3 signaling proceeded through both LGR-dependent and independent mechanisms because disruption of the FU2 or the TSP/BR domains partially impaired but did not abolish signaling (Figure 2C and F). The ZNRF3/RNF43-interacting FU1 domain is essential for signaling both in the presence and absence of LGRs.

To identify the region of RSPO3 that confers the capacity to signal without LGRs, we constructed a series of chimeric ligands by combining regions of RSPO1 and RSPO3 (Figure 3A). Remarkably, replacing the FU1 domain of RSPO1 with the FU1 domain of RSPO3 enabled RSPO1 to potentiate WNT signaling in LGR4/5/6 KO cells (Figure 3B and D). Conversely, replacing the FU1 domain of RSPO3 with that of RSPO1 drastically reduced the signaling capacity of RSPO3 in LGR4/5/6 KO cells (Figure 3B and D). In important control experiments, all chimeric ligands showed equivalent activity in WT cells, establishing ligand integrity (Figure 3B and C). Thus, a difference in the interaction between ZNRF3/RNF43 and the FU1 domains of RSPO1 and RSPO3 is the crucial determinant of the requirement for LGRs. Of note, the affinities of the FU1-FU2 fragment of RSPO2 (25 nM) and RSPO3 (60 nM) for ZNRF3 have been reported to be much higher than those of RSPO1 (6.8 μM) and RSPO4 (300 μM) (Zebisch et al., 2013). Indeed, these affinities correlate with the capacity of RSPO2 and RSPO3, but not RSPO1 or RSPO4, to promote LGR-independent signaling (Figure 1B). While the TSP/BR domains of RSPO3 were required for LGR-independent signaling, they were not sufficient because replacing the TSP/BR domains of RSPO1 with those of RSPO3 did not confer on RSPO1 the capacity to signal in LGR4/5/6 KO cells (Figure 3E). In fact, the TSP/BR domains of RSPO1 and RSPO3 seemed interchangeable for signaling activity in both WT and LGR4/5/6 KO cells (Figure 3E).

These results suggested that the WNT-potentiating activity of RSPO3 in the absence of LGRs depends on its interaction with ZNRF3/RNF43 through the FU1 domain and additional interactions with an alternative co-receptor through the TSP/BR domains. We considered the previous observation that the TSP/BR domains of RSPOs can bind to heparin (Nam et al., 2006). Addition of heparin to the culture medium completely blocked potentiation of WNT signaling by RSPO3 in LGR4/5/6 KO cells, but had only a partial inhibitory effect in WT cells, in which RSPO3 can also signal through LGRs (Figure 4A).

The TSP/BR domains of RSPOs can mediate interactions with the two major families of cell-surface HSPGs, the glycosphatidylinositol (GPI)-linked glypicans and the transmembrane syndecans (Ohkawara et al., 2011). In humans, both protein families are encoded by multiple, partially redundant genes: six glypican genes (GPC1-6) and four syndecan genes (SDC1-4) (Park et al., 2000), all of which are expressed in HAP1 cells except for GPC5 (Table 1). Since all glypicans and syndecans must be post-translationally modified with heparan sulfate chains for receptor function, we disrupted EXTL3, a gene encoding a glycosyltransferase that is specifically required for HSPG biosynthesis, but dispensable for the synthesis of other glycosaminoglycans and proteoglycans (Takahashi et al., 2013).
Figure 3. Domains of RSPO3 sufficient to confer the capacity to signal without LGRs. (A) Schematic representation of human WT and chimeric RSPO1 (salmon) and RSPO3 (violet) proteins, depicted as in Figure 2A. Vertical dotted lines indicate the sites at which swaps were made. Each swap was made at a conserved amino acid indicated under each construct (the amino acid numbers on the left and right of the slash correspond to the proteins depicted on the left and right of the dotted line, respectively). (B and E) Fold-induction in WNT reporter fluorescence (over 1.43% WNT3 CM alone) as Figure 3 continued on next page
2009). The loss of EXT3 in LGR4/5/6KO cells led to an 81% reduction in RSPO3-mediated potentiation of WNT signaling (Figure 4B). In contrast, the loss of EXT3 in WT cells only reduced signaling by 34%, likely because RSPO3 can also signal through LGRs in WT cells. In an important control, the loss of EXT3 did not affect signaling induced by addition of a sub-saturating concentration of WNT3A alone or by inhibition of the β-catenin destruction complex kinase GSK3 in either WT or LGR4/5/6KO cells (Figure 4—figure supplement 1A).

To distinguish between glypicans and syndecans, we took advantage of the fact that only glypicans are anchored to the cell surface by a GPI linkage. Disrupting PIgL, a gene required for GPI-anchor biosynthesis, or disrupting both GPC4 and GPC6, the two glypican genes identified in our previous haploid genetic screens (Lebensohn et al., 2016), in LGR4/5/6KO cells did not impair LGR-independent potentiation of WNT signaling by RSPO3 (Figure 4C). As we had found previously in WT HAP1-7TGP cells (Lebensohn et al., 2016), disrupting PIgL or GPC4 and GPC6 in LGR4/5/6KO cells reduced signaling by a sub-saturating dose of WNT3A (Figure 4—figure supplement 1B), indicating that glypicans are required to mediate cellular responses to low doses of WNT3A. Disrupting all four syndecans (SDC1-4) simultaneously in LGR4/5/6KO cells did not impair LGR-independent potentiation of WNT signaling by RSPO3 (Figure 4D), nor signaling induced by sub-saturating WNT3A or by inhibition of GSK3 (Figure 4—figure supplement 1C).

We conclude from these results that either glypicans or syndecans (or another HSPG) can mediate LGR-independent signaling, probably through interactions between their heparan sulfate chains and the TSP/BR domains of RSPO3. Therefore, disrupting any single family of HSPGs does not impair signaling (Figure 4C and D), while disrupting EXT3L, an enzyme required for the biosynthesis of heparan sulfate chains present in all HSPGs, substantially reduces LGR-independent signaling (Figure 4B).

Discussion

Our study shows that RSPOs can potentiate WNT signals in the absence of LGRs, expression of which has been hitherto considered the hallmark of RSPO-responsive cells. This quality is unique to RSPO2 and RSPO3 and is endowed by their ZNRF3/RNF43-interacting FU1 domain, since transplanting the FU1 domain from RSPO3 renders RSPO1 capable of signaling in the absence of LGRs (Figure 3B, D). Furthermore, the TSP/BR domains of RSPO3, which had been deemed dispensable for LGR-dependent signaling (Glinka et al., 2011), are necessary for signaling in the absence of LGRs (Figure 2E, G). HSPGs, cell surface proteins capable of interacting with the TSP/BR domains (Ohkawara et al., 2011), are also selectively required for RSPO3-dependent potentiation of WNT signaling in the absence of LGRs (Figure 4B). Thus, our results suggest that the interaction of the TSP/BR domains of RSPO3 with HSPGs provides an alternative mechanism that neutralizes ZNRF3/RNF43 in the absence of LGRs (Figure 4E). HSPGs are known to mediate the efficient endocytosis of multiple cargoes (Christianson and Belting, 2014). Hence, we speculate that the simultaneous interaction of RSPO3 with ZNRF3/RNF43 through its FU1 domain and HSPGs through its TSP/BR domains provides an LGR-independent route for the endocytosis and clearance of ZNRF3/RNF43 from the cell surface (Figure 4E) and the consequent rise in WNT receptor levels.

Future work will be necessary to define the developmental, regenerative or oncogenic contexts in which this LGR-independent mode of signaling is used to amplify target cell responses to WNT ligands. The presence of three LGRs capable of mediating responses to four RSPO ligands (de Lau et al., 2011) poses significant experimental challenges to addressing this question genetically in mouse models, as we did in human haploid cells, since multiple genes would need to be simultaneously disrupted to test if any responses to RSPOs are retained in tissues lacking all three LGRs.

However, some information can be gleaned from the developmental phenotypes of mice carrying mutations in Rspo2 or Rspo3, the two members of the family capable of potentiating WNT signaling in cells lacking all three LGRs (Figure 1B). Rspo2 is expressed in the limb and lung buds of the early
Figure 4. LGR-independent signaling by RSPO3 requires heparan sulfate proteoglycans. (A) WNT reporter induction in WT HAP1-7TGP and LGR4/5/6<sup>−/−</sup> cells treated with 1.43% WNT3A CM, 2 nM untagged RSPO3 and the indicated concentrations of heparin. For each heparin concentration, the fold-induction (over 1.43% WNT3A CM alone) by RSPO3 was calculated from the median WNT reporter fluorescence from 5000 cells and is expressed as percentage of the fold-induction in the absence of heparin to facilitate comparisons. (B–D) WNT reporter induction following treatment of the indicated...
Embryo and Rspo2−/− mice have defects in both limb development and branching of bronchioles in the developing lung (Nam et al., 2007a; Nam et al., 2007b; Bell et al., 2008). Rspo3 has been shown to be important for angioblast and vascular development and Rspo3−/− mouse embryos die around day E10 due to defects in placental vascularization (Aoki et al., 2007; Kazanskaya et al., 2008). While all three Lgrs have not been knocked out simultaneously in mice, Lgr4−/−; Lgr5−/− double knock-out embryos have impaired development of the intestine, kidney and skin (Kinzel et al., 2014). We speculate that the lung, limbs and vasculature, which depend on Rspo2 or Rspo3 but not Lgr4 and Lgr5 function, are tissues in which the LGR-independent mode of signaling may be important during development.

While LGRs are specifically expressed in some stem cell compartments (Clevers et al., 2014), HSPGs are expressed ubiquitously on the surface of most cells (Park et al., 2000). Thus, LGR-mediated RSPO signaling may be critical when high-level WNT signaling must be restricted to specific cells, as in the stem cell niches of various tissues, while HSPG-mediated RSPO signaling might confer amplification of WNT responses more broadly during the development of organs like the limbs, the lungs or the placenta.

In summary, our results define two alternative modes of RSPO-mediated amplification of WNT/β-catenin signaling that differ in their use of either LGRs or HSPGs (Figure 4E). The mutant and chimeric RSPO ligands we described should allow the selective modulation of these alternate modes of signaling.

Note added in proof
We recently became aware of soon-to-be published experiments from Bruno Reversade and colleagues (E. Szenker-ravi et al., 2018) that suggest an LGR-independent role for RSPOs during mouse development.
**Plasmids**

pCXsec-Tev-Fc (unpublished) was a gift from Henry Ho (University of California Davis, Davis, CA).
pHLsec-HA-Avi-1D4 (unpublished, derived from pHLSec (Aricescu et al., 2006) by incorporating a C-terminal HA tag following the signal sequence and an N-terminal Gly/Ser linker, AviTag biotinylation sequence and 1D4 tag [Molday and Molday, 2014]) was a gift from Christian Siebold (University of Oxford, Oxford, United Kingdom). RSPO1-GFP (Ruffner et al., 2012) was a gift from Feng Cong (Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, MA). MGC Human RSPO3 Sequence-Verified cDNA was purchased (GE Dharmacon Cat. # MH56278-202841214). pX330-U6-Chimeric_BB-CBh-hSpCas9 (pX330) was a gift from Feng Zhang (Addgene plasmid # 42230). pX333 was a gift from Andrea Ventura (Addgene plasmid # 64073).

pHLsec-HA-hRSPO1-Tev-Fc-Avi-1D4 and pHLsec-HA-hRSPO3-Tev-Fc-Avi-1D4 were constructed through a two-step subcloning strategy. In the first step, human RSPO1 and human RSPO3 were amplified by PCR with forward primers pCX-RSPO1-F (5’- GAG GCT AGC ACC ATG CGG CTT GGG CTG TGT G-3’) or pCX-RSPO3-F (5’-GAG GCT AGC ACC ATG CAC TTG CGA CTG ATT TCT TG-3’), containing an NheI restriction site, and reverse primers pCX-RSPO1-R (5’-TGA GGT ACC AAG GCA GGC CCT GCA GAT GTG-3’) or pCX-RSPO3-R (5’- TGA GGT ACC AAG TGT ACA GTG CTG ACT GAT ACC GA-3’), containing a KpnI restriction site. The products were digested with NheI and KpnI and subcloned into pCX-Tev-Fc digested at the same sites to obtain pCX-hRSPO1-Tev-Fc and pCX-hRSPO3-Tev-Fc.

In the second step, a fragment containing RSPO1 or RSPO3 followed by two tandem Tev cleavage sites, a linker and the Fc domain of human IgG was amplified by PCR from pCX-hRSPO1-Tev-Fc or pCX-hRSPO3-Tev-Fc, respectively, using forward primers pHL-SEC-RSPO1-F-gibson (5’- CGA CGT GCC CGA CTA CGC CAC CGG TAA CCT GAG CCG GGG GAT CAA GGG G-3’) or pHL-SEC-RSPO3-F-gibson (5’- CGA CGT GCC CGA CTA CGC CAC CGG TAA CCT GCA AAA CGC CTC CGG GG-3’) and reverse primer pHL-SEC-FC-R-gibson-no-KpnI (5’- ACC ACC GGA ACC TCC GGT ACT TTT ACC CGG AGA CAG GGA GA-3’). The forward and reverse primers contained 24 base pair (bp) overhangs complementary to pHLsec-HA-Avi-1D4 upstream of the unique AgeI site and downstream of the unique KpnI site in the vector, respectively. The reverse primer contained a mutation that eliminated the KpnI site in pHLsec-HA-Avi-1D4, hence retaining only one KpnI site between RSPO1 or RSPO3 and the Tev cleavage sites in the resulting construct. The PCR products were subcloned by Gibson assembly (using Gibson Assembly Master Mix, NEB Cat. # E2611L) into pHLsec-HA-Avi-1D4 digested with AgeI and KpnI, using the NEBuilder HiFi DNA Assembly Master Mix (NEB Cat. # E2621L).

Human RSPO1 and RSPO3 mutants and chimeras (Figures 2A and 3A and Supplementary file 2) were generated synthetically as gBlocks Gene Fragments (IDT), flanked at the 5’ and 3’ ends, respectively, by 24 bp overhangs overlapping the sequence upstream of the unique AgeI site and downstream of the unique KpnI site in the vector, respectively. The gBlocks were subcloned into pHLsec-HA-Tev-Fc-Avi-1D4 and pHLsec-HA-hRSPO3-Tev-Fc-Avi-1D4, which contain a single AgeI site upstream and a single KpnI site downstream of the RSPO coding sequence. Henceforth, we refer to the vector backbone of this new constructs as pHLsec-HA-Tev-Fc-Avi-1D4.

To remove the dimerizing Fc tag from RSPO3 ΔTSP/BR in order to make the protein used in Figures 2F and G, a fragment lacking the TSP and BR domains of RSPO3 was amplified by PCR using forward primer pHL-SEC-RSPO3-F-gibbon (sequence described above) and reverse primer pHL-SEC-AVI-1D4-RSPO3FU2-R-gibson (5’-AGA CCG GAA CCA CCG GAA CCT CCG GTA CCC ACA ATA CTG ACA CAC TCC ATA GTA GTG TTG T-3’), containing 24 bp overhangs complementary to pHLsec-HA-Avi-1D4 upstream of the unique AgeI site and downstream of the unique KpnI site in the vector, respectively. The PCR product and pHLsec-HA-Avi-1D4 vector were both digested with AgeI and KpnI and ligated to produce pHLsec-HA-hRSPO3ΔTSP/BR-Avi-1D4. All constructs were sequenced fully and have been deposited in Addgene.

**Analysis of WNT reporter fluorescence**

To measure WNT reporter activity in HAP1-7TGP cells (Lebensohn et al., 2016) or derivatives thereof, ~24 hr before treatment cells were seeded in 96-well plates at a density of 1.5 x 10^4 per well and grown in 100 µl of complete growth medium (CGM) 2 (Lebensohn et al., 2016). Cells were
treated for 20–24 hr with the indicated concentrations of WNT3A CM (Lebensohn et al., 2016), untagged recombinant human R-Spondin 1, 2, 3 or 4 (R&D Systems Cat. # 4645-RS, 3266-RS, 3500-RS or 4575-RS, respectively), tagged RSPO1–4 proteins (see below) or CHIR-99021 (CT99021) (Selleckchem Cat. # S2924), all diluted in CGM 2. Cells were washed with 100 µl phosphate buffered saline (PBS), harvested in 30 µl of 0.05% trypsin-EDTA solution (Gemini Bio-Products Cat. # 400–150), resuspended in 120 µl of CGM 2 and EGFP fluorescence was measured immediately by FACS on a BD LSRRFortessa cell analyzer (BD Biosciences) using a 488 laser and 505LP, 530/30 BP filters, or on a BD Accuri RUO Special Order System (BD Biosciences).

For the experiments shown in Figures 1C, 2B, E, 3B, E and 4B–D and Figure 4—figure supplement 1C and D, cells were treated in duplicate or triplicate wells, fluorescence data for 5000–10,000 singlet-gated cells was collected and the median EGFP fluorescence for each well was depicted and/or used to calculate other parameters depicted, as indicated in the figure legends. For the experiments shown in Figures 1A,B, 2C, D, F, G, 3C, D, 4A and Figure 1—figure supplement 1C and D, cells were treated in single wells and fluorescence data for 5000–10,000 singlet-gated cells was collected. The median EGFP fluorescence and in some cases the standard error of the median (SEM = 1.253 σ / √n, where σ = standard deviation and n = sample size) from each well were depicted. Dose-response curves were fitted using the nonlinear regression (curve fit) analysis tool in GraphPad Prism 7 using the [agonist] vs. response – variable slope (four parameters) equation (Figure 1C, 2C, D, F, G, 3C, D and Figure 1—figure supplement 1C and D) or the [inhibitor] vs. response – variable slope (four parameters) equation (Figure 4A), both with least squares (ordinary) fit option. Results presented are representative of experiments repeated at least twice.

Construction of mutant HAP1-7TGP cell lines by CRISPR/Cas9-mediated genome editing

Oligonucleotides encoding single guide RNAs (sgRNAs) (Supplementary file 3) were selected from one of two published libraries (Wang et al., 2015; Doench et al., 2016) or designed using the ‘Guide Picker’ tool of the DESKGEN Cloud CRISPR design software (https://www.deskgen.com/landing/cloud.html). Oligonucleotides were cloned into the single cloning site of pX330 according to a published protocol (Cong et al., 2013) (original version of ‘Target Sequence Cloning Protocol’ from http://www.genome-engineering.org/crispr/wp-content/uploads/2014/05/CRISPR-Reagent-Description-Rev20140509.pdf), or sequentially into the two cloning sites of pX333 (Maddalo et al., 2014) by digesting the plasmid at each site and ligating the oligonucleotides as described for pX330.

Clonal cell lines derived from HAP1-7TGP were established by transient transfection with pX330 or pX333 containing the desired sgRNAs, followed by single-cell sorting as described previously (Lebensohn et al., 2016). Genotyping was done as described previously (Lebensohn et al., 2016) using the primers indicated in Supplementary file 3 and the results are summarized in Supplementary file 1. To generate triple, quadruple, quintuple and septuple knock-out (KO) cell lines, a single clonal cell line harboring the first desired mutation or mutations was used in subsequent rounds of transfection with pX330 or pX333 containing additional sgRNAs, followed by single-cell sorting. To facilitate screening of mutant clones by PCR when targeting multiple genes simultaneously, we sometimes targeted one of the genes at two different sites within the same exon or in adjacent exons and amplified genomic sequence encompassing both target sites. Mutant clones were readily identified by the altered size of the resulting amplicon and the precise lesions were confirmed by sequencing the single allele of each gene.

Production of tagged RSPO proteins by transient transfection of 293T cells and immuno-affinity purification from conditioned media (see Figure 1—figure supplement 1A)

~24 hr before transfection, 14 × 10⁶ 293T cells were seeded in each of two T-175 flasks containing 30 ml of CGM 1 (Lebensohn et al., 2016) for transfection with each construct. Once they had reached 60–80% confluency, the cells in each flask were transfected with 1 ml of a transfection mix prepared as follows: 22.3 µg of pHLsec-HA-hRSPO-Tev-Fc-Avi-1D4 construct encoding tagged WT, mutant or chimeric RSPO proteins was diluted in 930 µl of serum-free DMEM (GE Healthcare Life Sciences Cat. # SH30081.01) and 70 µl of polyethylenimine (PEI, linear, MW ~25,000, Polysciences, Inc. Cat. # 23966) were added from a 1 mg/ml stock (prepared in sterile water, stored frozen and
equilibrated to 37°C before use). The transfection mix was vortexed briefly, incubated for 15–20 min at room temperature (RT) and added to the cells without replacing the growth medium. ~16 hr post-transfection, the cells were washed with 30 ml PBS and the medium was replaced with 28 ml of CD 293 medium (Thermo Fisher Scientific Cat. # 11913019) supplemented with 1x L-glutamine solution (stabilized, Gemini Bio-Products Cat. # 400–106), 1x penicillin/streptomycin solution (Gemini Bio-Products Cat. # 400–109) and 2 mM valproic acid (Sigma-Aldrich Cat. # P4543, added from a 0.5 M stock prepared in water and sterilized by filtration through a 0.22 μm filter) to promote protein expression.

~90 hr post-transfection, the CM from each of the two flasks, containing secreted RSPO protein, was harvested and centrifuged for 5 min at 400 x g to pellet detached cells. The supernatant was centrifuged for 5 min at 4000 x g and filtered through 0.45 μm filters (Acrodisc syringe filters with Supor membrane, Pall Corporation) to remove particulates and was reserved on ice.

Prior to the purification, Rho 1D4 immuno-affinity resin was prepared by coupling Rho 1D4 purified monoclonal antibody (University of British Columbia, https://uilo.ubc.ca/rho-1d4-antibody) to CNBr-activated sepharose 4B (GE Healthcare Life Sciences Cat. # 17-0430-01). Briefly, 1 g of dry CNBr-activated sepharose 4B was dissolved in 50 ml of 1 mM HCl and allowed to swell. The resin was transferred to an Econo-Pac chromatography column (Biorad Cat. # 7321010) and washed by gravity flow with 50 ml of 1 mM HCl, followed by 50 ml of 0.1 M NaHCO₃, 0.5 M NaCl, pH 8.5. 14 mg of Rho 1D4 antibody were dissolved in 0.1 M NaHCO₃, 0.5 M NaCl, pH 8.5 and incubated with the resin overnight, rotating at 4°C. The resin was washed with 50 ml of 0.2 M glycine, pH 8.0 and incubated in the same buffer for 2 hr, rotating at RT. The resin was washed sequentially with 50 ml each of: 0.1 M NaHCO₃, 0.5 M NaCl, pH 8.5; 0.1 M NaOAc, 0.5 M NaCl, pH 4.0; 0.1 M NaHCO₃, 0.5 M NaCl, pH 8.5; PBS, 10 mM NaN₃. The packed resin was resuspended in an equal volume of PBS, 10 mM NaN₃ to make a ~50% slurry, aliquoted and stored at 4°C.

300 μl of the ~50% slurry of Rho 1D4 resin was added to a 50 ml conical tube containing the RSPO CM and the suspension was incubated 10 hr rocking at 4°C. Following binding and during all subsequent washes the resin was collected by centrifugation for 5 min at 400 x g in a swinging bucket rotor. The beads were washed three times at RT with 25 ml PBS by resuspending the beads in buffer and mixing by inversion for ~1 min. The resin was transferred to a 1.5 ml Eppendorf tube and washed three more times with 1.4 ml of PBS, 10% glycerol.

Following the last wash, the buffer was aspirated and the resin was resuspended in 150 μl of PBS, 10% glycerol to obtain a ~50% slurry. Tagged RSPO protein was eluted by adding 3 μl of a 25 mM stock of 1D4 peptide ((NH₂)-T-E-T-S-Q-V-A-P-A-(COOH)) for a final concentration of 250 μM. Elution was carried out by rotating the tube horizontally overnight at 4°C. Following centrifugation of the resin, the eluate was recovered and reserved on ice. The resin was resuspended in 150 μl of PBS, 10% glycerol and 250 μM 1D4 peptide was added. A second round of elution was carried out for 1 hr at RT. Following centrifugation of the resin, the second eluate was recovered and pooled with the first. The final eluate was centrifuged once again to remove residual resin and the supernatant containing tagged RSPO proteins was aliquoted, frozen in liquid nitrogen and stored at −80°C.

Quantification of tagged RSPO proteins (see Figure 1—figure supplement 1B)

4.5 μl and 13.5 μl of the final eluates containing tagged RSPO proteins were diluted with 4x LDS sample buffer (Thermo Fisher Scientific Cat. # NP0007) supplemented with 50 mM tris(2-carboxyethyl)phosphine (TCEP), heated for 10 min at 95°C and loaded onto NuPAGE 4–12% Bis-Tris gels (Thermo Fisher Scientific) alongside Precision Plus Protein molecular weight standards (Bio-Rad Cat. # 1610373) and bovine serum albumin (BSA) standards (Thermo Fisher Scientific Cat. # 23209) for quantification. Proteins were electrophoresed in 1x NuPAGE MES SDS running buffer (Thermo Fisher Scientific Cat. # NP0002).

Gels were fixed in 50% methanol, 7% acetic acid for 30 min, rinsed with several changes of water for 1.5 hr, stained with GelCode Blue Stain Reagent (Thermo Fisher Scientific Cat. # 24590) for 2 hr, de-stained in water overnight and imaged using the Li-Cor Odyssey imaging system. Acquisition parameters for coomassie fluorescence (700 nm channel) were set so as to avoid saturated pixels and bands with intensities within the linear range of fluorescence for the BSA standards were quantified using manual background subtraction.
Immunoblot analysis of tagged RSPO proteins (see Figure 1—figure supplement 1B)

50 ng of tagged RSPO proteins were electrophoresed as described above and transferred to nitrocellulose membranes in a Criterion Blotter apparatus (Bio-Rad Cat. # 1704071) using 1x NuPAGE transfer buffer (Thermo Fisher Scientific Cat. # NP0006) containing 10% methanol. Membranes were blocked with Odyssey Blocking Buffer (Li-Cor Cat. # 927–40000) for 1 hr at RT and incubated overnight at 4°C with purified anti-HA.11 Epitope Tag primary antibody (BioLegend Cat. # 901501; previously Covance cat. # MMS-101P) diluted 1:1500 in blocking solution (a 1 to 1 mixture of Odyssey Blocking Buffer and TBST (Tris buffered saline (TBS), 0.1% Tween-20)). Membranes were washed with TBST, incubated for 1 hr at RT with IRDye 800CW donkey anti-mouse IgG (H + L) (Li-Cor Cat. # 926–32212) diluted 1:10,000 in blocking solution, washed with TBST followed by TBS and imaged using the Li-Cor Odyssey imaging system.

Preparation of figures and statistical analysis

Illustrations were prepared using PowerPoint (Microsoft) and Illustrator CS6 (Adobe). Bar graphs, dose-response graphs and circle graphs were prepared using Prism 7 (GraphPad Software) and statistical analysis was performed using the same software. For comparisons between two datasets, significance was determined by unpaired t test; for comparisons between more than two datasets, significance was determined by one-way ANOVA. Significance is indicated as **** (p<0.0001), ** (p<0.01), * (p<0.05) or ns (not significant). Pictures of gels and immunoblots were only adjusted for contrast and brightness using Photoshop CS6 (Adobe) and were arranged in Illustrator CS6.

Data availability

All data generated or analyzed during this study are included in this published article (and its supplementary information files). The RNAseq dataset used in Table 1 is publicly available (NCBI GEO accession number GSE75515, https://www.ncbi.nlm.nih.gov/geo/).

Acknowledgements

We thank Jan Carette and Rohatgi lab members for input on the project, Henry Ho for pCX-Tev-Fc, Christian Siebold for pHLsec-HA-Avi-1D4 and Feng Cong for RSPO1-GFP. This work was funded by NIH grants DP2 GM105448 and R35 GM118082 to RR. AML was supported by the Stanford Dean’s Postdoctoral Fellowship, the Stanford Cancer Biology Program Training Grant and the Novartis sponsored Fellowship from the Helen Hay Whitney Foundation. The authors declare no conflicting financial interests.

Additional information

Funding

| Funder                                      | Grant reference number | Author               |
|---------------------------------------------|------------------------|----------------------|
| National Institutes of Health                | GM105448               | Rajat Rohatgi        |
| National Institutes of Health                | GM118082               | Rajat Rohatgi        |
| Helen Hay Whitney Foundation Fellowship      | Novartis Post-Doctoral | Andres M Lebensohn   |
| Stanford University School of Medicine      | Dean’s Post-Doctoral   | Andres M Lebensohn   |
| Stanford University School of Medicine      | Cancer Biology Training Grant | Andres M Lebensohn   |

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Author contributions
Andres M Lebensohn, Conceptualization, Formal analysis, Investigation, Methodology, Writing—original draft, Writing—review and editing; Rajat Rohatgi, Conceptualization, Supervision, Funding acquisition, Methodology, Writing—original draft, Project administration, Writing—review and editing

Author ORCIDs
Andres M Lebensohn https://orcid.org/0000-0002-4224-8819
Rajat Rohatgi https://orcid.org/0000-0001-7609-8858

Decision letter and Author response
Decision letter https://doi.org/10.7554/eLife.33126.016
Author response https://doi.org/10.7554/eLife.33126.017

Additional files

Supplementary files
- Supplementary file 1. Description of engineered cell lines used in this study. Clonal cell lines derived from HAP1-7TGP in which a single or multiple genes were targeted using CRISPR/Cas9 are described in two separate spreadsheets labeled accordingly. When more than one clonal cell line was generated targeting the same gene or genes, the ‘Cell Line Name’ column indicates the generic name used throughout the manuscript to describe the genotype and the ‘Clone #’ column identifies distinct individual clones. The figures in which each clone was used are also indicated. The ‘CRISPR guide’ column indicates the name of the guide used, which is the same as that of the oligonucleotides encoding sgRNAs (see Materials and methods and Supplementary file 3). The ‘Genomic Sequence’ column shows 80 nucleotides of genomic sequence (5' relative to the gene is to the left) surrounding the target site; when two adjacent sites were targeted within the same gene, 80 nucleotides of genomic sequence surrounding each target site are shown and the number of intervening base pairs that are not shown between the two sites is indicated in parenthesis. Each group of clonal cell lines made using the same CRISPR guides is separated by a horizontal spacer and the ‘Genomic Sequence’ column is headlined by the reference WT genomic sequence (obtained from RefSeq). The guide sequence is colored blue and the site of the double strand cut made by Cas9 is between the two underlined bases. Sequencing results for individual clones are indicated below the reference sequence. Rare differences between the reference RefSeq sequence and the sequencing result obtained from HAP1-7TGP clones, as well as any undetermined sequences, are indicated in green. Some clones obtained following transfection with the indicated sgRNAs and single-cell sorting were found to be WT at the target site or sites; these are indicated as such and were used as controls. For mutant clones, mutated nucleotides are colored red (dashes represent deleted nucleotides, ellipses are used to indicate that a deletion continues beyond the 80 nucleotides of sequence shown and large insertions are indicated in brackets) and the nature of the mutation, the resulting genotype and any pertinent observations are also described. For clones in which multiple genes were targeted, the CRISPR guide (or pair of guides) used to target each gene as well as the genomic sequence, mutation, genotype and observations pertaining to each of the targeted genes are designated ‘1’, ‘2’, ‘3’ and so on in the column headings and are shown under horizontal spacers of different colors.
DOI: https://doi.org/10.7554/eLife.33126.009

- Supplementary file 2. Nucleotide sequences of RSPO1 and RSPO3 WT, mutant and chimeric constructs used in this study. The name and length of each construct is indicated. Lowercase sequences overlap the sequence upstream of the unique Agel site and downstream of the unique Kpnl site in the pHLsec-HA-Tev-Fc-Avi-1D4 vector. Uppercase sequences encode human RSPO1 and RSPO3 WT, mutant and chimeric constructs. For point mutants, mutated codons are underlined.
DOI: https://doi.org/10.7554/eLife.33126.010

- Supplementary file 3. List of oligonucleotides and primers used to generate and characterize clonal cell lines engineered using CRISPR/Cas9. The names and sequences of pairs of oligonucleotides encoding sgRNAs (which were cloned into pX330 or pX333) are shown in the first and second
columns, respectively. The names and sequences of pairs of PCR primers used to amplify corresponding genomic regions flanking sgRNA target sites are shown in the third and fourth columns, respectively. The names and sequences of primers used to sequence the amplified target sites are shown in the fifth and sixth columns, respectively.

DOI: https://doi.org/10.7554/eLife.33126.011

• Transparent reporting form

DOI: https://doi.org/10.7554/eLife.33126.012

Major datasets

The following previously published dataset was used:

| Author(s)          | Year  | Dataset title                                                                 | Dataset URL                                                                 | Database, license, and accessibility information |
|--------------------|-------|------------------------------------------------------------------------------|----------------------------------------------------------------------------|--------------------------------------------------|
| Dubey R, Lebensohn A, Bahrami-Nejad Z, Marceau C, Sikic Bl, Carette J, Rohatgi | 2016  | Gene expression analysis of human haploid cells (HAP1) depleted of SMARCB1 and SMARCA4 | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE75515 | Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE75515) |

References

Aoki M, Mieda M, Ikeda T, Hamada Y, Nakamura H, Okamoto H. 2007. R-spondin3 is required for mouse placental development. Developmental Biology 301:218–226. DOI: https://doi.org/10.1016/j.ydbio.2006.08.018, PMID: 16963017

Aricescu AR, Lu W, Jones EY. 2006. A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallographica Section D Biological Crystallography 62:1243–1250. DOI: https://doi.org/10.1107/S0907444906299799, PMID: 1700101

Bell SM, Schreiner CM, Wert SE, Mucenski ML, Scott WJ, Whitsett JA. 2008. R-spondin 2 is required for normal laryngeal-tracheal, lung and limb morphogenesis. Development 135:1049–1058. DOI: https://doi.org/10.1242/dev.013359, PMID: 18256198

Carmon KS, Gong X, Lin Q, Thomas A, Liu Q. 2011. R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/beta-catenin signaling. PNAS 108:11452–11457. DOI: https://doi.org/10.1073.pnas.1106083108, PMID: 21693646

Chen PH, Chen X, Lin Z, Fang D, He X. 2013. The structural basis of R-spondin recognition by LGR5 and RNF43. Genes & Development 27:1345–1350. DOI: https://doi.org/10.1101/gad.219915.113, PMID: 23756651

Christianson HC, Beltling M. 2014. Heparan sulfate proteoglycan as a cell-surface endocytosis receptor. Matrix Biology 35:51–55. DOI: https://doi.org/10.1016/j.matbio.2013.10.004, PMID: 24145152

Clevers H, Loh KM, Nusse R. 2014. Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science 346:1248012. DOI: https://doi.org/10.1126/science.1248012, PMID: 25278615

Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F. 2013. Multiplex genome engineering using CRISPR/Cas systems. Science 339:819–823. DOI: https://doi.org/10.1126/science.1231143, PMID: 23268718

de Lau W, Barker N, Low TY, Koo BK, Li VS, Teunissen H, Kujala P, Haegearth A, Peters PJ, van de Wetering M, Stange DE, van Es JE, Guardavaccaro D, Schasfoort RB, Mohri Y, Nishimori K, Mohammed S, Heck AJ, Clevers H. 2011. Lgr5 homologues associate with Wnt receptors and mediate R-spondin signaling. Nature 476:293–297. DOI: https://doi.org/10.1038/nature10337, PMID: 21727895

de Lau W, Peng WC, Gros P, Clevers H. 2014. The R-spondin/Lgr5/Rnf43 module: regulator of Wnt signal strength. Genes & Development 28:305–316. DOI: https://doi.org/10.1101/gad.235473.113, PMID: 24532711

de Lau WB, Snel B, Clevers HC. 2012. The R-spondin protein family. Genome Biology 13:242. DOI: https://doi.org/10.1186/gb-2012-13-3-242, PMID: 22439850

Doech JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE. 2016. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nature Biotechnology 34:184–191. DOI: https://doi.org/10.1038/nbt.3437, PMID: 26780180

Dubey R, Lebensohn AM, Bahrami-Nejad Z, Marceau C, Champion M, Gevaert O, Sikic Bl, Carette J, Rohatgi R. 2016. Chromatin-Remodeling complex SWI/SNF controls multidrug resistance by transcriptionally regulating the drug efflux pump ABCB1. Cancer Research 76:5810–5821. DOI: https://doi.org/10.1158/0008-5472.CAN-16-0716, PMID: 27503929

Glinka A, Dolce C, Kirsch N, Huang YL, Kazanskaya O, Ingelfinger D, Boutros M, Cruciat CM, Niehrs C. 2011. LGR4 and LGR5 are R-spondin receptors mediating Wnt/beta-catenin and Wnt/PCP signalling. EMBO Reports 12:1055–1061. DOI: https://doi.org/10.1038/embor.2011.175, PMID: 21909076

Hao H-X, Jiang X, Cong F. 2016. Control of Wnt Receptor Turnover by R-spondin-ZNRF3/RNF43 Signaling Module and Its Dysregulation in Cancer. Cancers 8:54. DOI: https://doi.org/10.3390/cancers8060054
Xie Y, Wang T, Ruffner H, Peng WC, Park PW, Ohkawara B, Nam JS, Nam JS, Nam JS, Lebensohn AM, Koo BK, Kazanskaya O, Kazanskaya O, Hao HX, Yamauchi A, Shervani NJ, Uruno A, Kato I, Unno M, Sugahara K, Takasawa S, Okamoto H, Sugawara A. 2009. Isken A, Xie Y, Zhang Y, Hao H, Shi X, Liu D, Song Q, Clay I, Hintzen G, Tchorz J, Bouchez LC, et al. 2012. R-spondin1 acts as a Wnt activator and promotes endocytosis to promote morphogenesis. Developmental Cell 21:303–314. DOI: https://doi.org/10.1016/j.devcel.2011.01.006

Maddaloni D. 2018. Multiple roles for heparan sulfate in embryonic development and disease. Developmental Biology and Stem Cells 1:252–534. DOI: https://doi.org/10.1016/j.devbio.2004.07.019, PMID: 15469841

Kazanskaya O, Ohkawara B, Heroult M, Wu W, Maltry N, Augustin HG, Niehrs C. 2008. The Wnt signaling regulator R-spondin3 promotes angioblast and vascular development. Development 135:3655–3664. DOI: https://doi.org/10.1242/dev.027284, PMID: 18842812

Kinzel B, Pikiulek M, Orsini V, Sprunger J, Isken A, Zietzing S, Desplanches M, Dubost V, Breustedt D, Valdez R, Liu D, Theil D, Müller M, Dietrich B, Bouwmeester T, Ruffner H, Tchorz JS. 2014. Functional roles of Lgr4 and Lgr5 in embryonic gut, kidney, and skin development in mice. Developmental Biology 390:181–190. DOI: https://doi.org/10.1016/j.ydbio.2014.03.009, PMID: 24680895

Koo BK, Spitz M, Jordens I, Low TY, Stange DE, van de Wetering M, van Es JH, Mohammed S, Heck AJ, Maurice MM, Clevers H. 2012. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature 488:665–669. DOI: https://doi.org/10.1038/nature11308, PMID: 22895187

Lebensohn AM, Dubey R, Neitzel LR, Tachelly-Benites O, Yang E, Marceau CD, Davis EM, Patel BB, Bahrami-Nejad Z, Travaglini KJ, Ahmed Y, Lee E, Cavette JE, Rohatgi R. 2016. Comparative genetic screens in human cells reveal new regulatory mechanisms in WNT signaling. eLife 5:e21459. DOI: https://doi.org/10.7554/eLife.21459, PMID: 27996937

Maddaloni D, Manchado E, Concepcion CP, Bonetti C, Vidigal JA, Han YC, Ogrodowski P, Crippa A, Rekhtman N, de Stanchina E, Lowe SW, Ventura A. 2014. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 516:423–427. DOI: https://doi.org/10.1038/nature13902, PMID: 25337876

Molday LL, Molday RS. 2014. 1D4: a versatile epitope tag for the purification and characterization of expressed membrane and soluble proteins. Methods in Molecular Biology 1177:1–15. DOI: https://doi.org/10.1007/978-1-4939-1034-2_1, PMID: 24943310

Nam JS, Park E, Turcotte TJ, Palencia S, Zhan X, Lee J, Yun K, Funk WD, Yoon JK. 2007a. Mouse R-spondin2 is required for apical ectodermal ridge maintenance in the hindlimb. Developmental Biology 311:124–135. DOI: https://doi.org/10.1016/j.ydbio.2007.08.023, PMID: 17904116

Nam JS, Turcotte TJ, Smith PF, Choi S, Yoon JK. 2006. Mouse cristin/R-spondin family proteins are novel ligands for the Frizzled 8 and LRP6 receptors and activate beta-catenin-dependent gene expression. Journal of Biological Chemistry 281:13247–13257. DOI: https://doi.org/10.1074/jbc.M508324200, PMID: 16543246

Nam JS, Turcotte TJ, Yoon JK. 2007b. Dynamic expression of R-spondin family genes in mouse development. Gene Expression Patterns 7:306–312. DOI: https://doi.org/10.1016/j.modgep.2006.08.006, PMID: 17035101

Okawara B, Glinka A, Niehrs C. 2011. Rspo3 binds syndecan 4 and induces Wnt/PCP signaling via clathrin-mediated endocytosis to promote morphogenesis. Developmental Cell 20:303–314. DOI: https://doi.org/10.1016/j.devcel.2011.01.006, PMID: 21379842

Park PW, Reizes O, Bernfield M. 2000. Cell surface heparan sulfate proteoglycans: selective regulators of ligand-receptor encounters. Journal of Biological Chemistry 275:29923–29926. DOI: https://doi.org/10.1074/jbc.R000008200, PMID: 10931855

Peng WC, de Lau W, Forneris F, Graneman JC, Hutch M, Clevers H, Gros P. 2013. Structure of stem cell growth factor R-spondin 1 in complex with the ectodomain of its receptor LGR5. Cell Reports 3:1885–1892. DOI: https://doi.org/10.1016/j.celrep.2013.06.009, PMID: 23809763

Ruffner H, Sprunger J, Charlat O, Leighton-Davies J, Grosshans B, Salathe A, Zietzing S, Beck V, Therier M, Isken A, Xie Y, Zhang Y, Hao H, Shi X, Liu D, Song Q, Clay I, Hintzen G, Tchorz J, Bouchez LC, et al. 2012. R-Spondin potentiates Wnt/beta-catenin signaling through orphan receptors LGR4 and LGR5. PLoS One 7:e40976. DOI: https://doi.org/10.1371/journal.pone.0040976, PMID: 22815884

Takahashi I, Noguchi N, Nata K, Yamada S, Kameiwa T, Mizumo S, Ikeda T, Sugihara K, Asano M, Yoshikawa T, Yamauchi A, Shervani NJ, Urano A, Kato I, Unno M, Sugahara K, Takasawa S, Okamoto H, Sugawara A. 2009. Important role of heparan sulfate in postnatal islet growth and insulin secretion. Biochemical and Biophysical Research Communications 383:113–118. DOI: https://doi.org/10.1016/j.bbrc.2009.03.140, PMID: 19336225

Wang D, Huang B, Zhang S, Yu X, Wu W, Wang X. 2013. Structural basis for R-spondin recognition by LGR4/5/6 receptors. Genes & Development 27:1339–1344. DOI: https://doi.org/10.1101/gad.219360.113, PMID: 23756652

Wang T, Birsoy K, Hughes NW, Krupczak KM, Post Y, Wei JJ, Lander ES, Sabatini DM. 2015. Identification and characterization of essential genes in the human genome. Science 350:1096–1101. DOI: https://doi.org/10.1126/science.aac7041, PMID: 26472758

Xie Y, Zamponi R, Charlat O, Ramones M, Swalley S, Jiang X, Rivera D, Tschantz W, Lu B, Quinn L, Dimitri C, Parker J, Jeffery D, Wilcox SK, Watrobka M, de Lau W, Forneris F, Granneman JC, Huch M, Clevers H, Gros P. 2013. Structure of stem cell growth factor R-spondin 1 in complex with the ectodomain of its receptor LGR5. Cell Reports 3:1885–1892. DOI: https://doi.org/10.1016/j.celrep.2013.06.009, PMID: 23809763

Xu K, Yu X, Rajashankar KR, Robev D, Nikolov DB. 2013. Crystal structures of Lgr4 and its complex with R-spondin1. Structure 21:1683–1689. DOI: https://doi.org/10.1016/j.str.2013.07.001, PMID: 23891289
Zebisch M, Xu Y, Krastev C, MacDonald BT, Chen M, Gilbert RJ, He X, Jones EY. 2013. Structural and molecular basis of ZNRF3/RNF43 transmembrane ubiquitin ligase inhibition by the Wnt agonist R-spondin. *Nature Communications* **4**:2787. DOI: https://doi.org/10.1038/ncomms3787, PMID: 24225776